Figure 1
From: NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life
Relapse-free survival by CDDI (<85%, ⩾85%).
Figure 1 | British Journal of Cancer
From: NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life
Relapse-free survival by CDDI (<85%, ⩾85%).
